{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "36693151",
  "DateCompleted": {
    "Year": "2023",
    "Month": "01",
    "Day": "26"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "03",
    "Day": "18"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1097/PPO.0000000000000643"
    ],
    "Journal": {
      "ISSN": "1540-336X",
      "JournalIssue": {
        "Volume": "29",
        "Issue": "1",
        "PubDate": {
          "MedlineDate": "2023 Jan-Feb 01"
        }
      },
      "Title": "Cancer journal (Sudbury, Mass.)",
      "ISOAbbreviation": "Cancer J"
    },
    "ArticleTitle": "Molecular Testing for Diagnostics, Prognostication, and Treatment Stratification in Cancers.",
    "Pagination": {
      "StartPage": "3",
      "EndPage": "8",
      "MedlinePgn": "3-8"
    },
    "Abstract": {
      "AbstractText": [
        "Precision cancer care, for essentially all cancer types, now requires molecular diagnostics to assess mutations, chromosomal alterations, and gene expression to personalize treatments for individual patients. Advances in the diagnostics and treatment options have moved the field forward from fundamental discoveries beginning in the 1960s to the development of many targeted therapies that can be as specific as targeting a single-base-pair mutation. Herein is a brief historical perspective on cancer precision medicine with current diagnostic, prognostic, and treatment stratification guidance for early- and late-stage cancers."
      ],
      "CopyrightInformation": "Copyright \u00a9 2023 Wolters Kluwer Health, Inc. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "From the Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA."
          }
        ],
        "LastName": "Heneidi",
        "ForeName": "Saleh",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Golden",
        "ForeName": "Jeffrey A",
        "Initials": "JA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Vail",
        "ForeName": "Eric",
        "Initials": "E"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Cancer J",
    "NlmUniqueID": "100931981",
    "ISSNLinking": "1528-9117"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "diagnosis",
        "genetics",
        "therapy"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mutation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prognosis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Precision Medicine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Molecular Diagnostic Techniques"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Molecular Targeted Therapy"
    }
  ],
  "CoiStatement": "Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article."
}